See more : Premier Graphene Inc (BIEI) Income Statement Analysis – Financial Results
Complete financial analysis of Avicanna Inc. (AVCN.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avicanna Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Maronan Metals Limited (MMA.AX) Income Statement Analysis – Financial Results
- Tsakos Energy Navigation Limited (TNP-PE) Income Statement Analysis – Financial Results
- Spectra Systems Corporation (SPSY.L) Income Statement Analysis – Financial Results
- Hunan Yujing Machinery Co.,Ltd (002943.SZ) Income Statement Analysis – Financial Results
- Frontier Springs Limited (FRONTSP.BO) Income Statement Analysis – Financial Results
Avicanna Inc. (AVCN.TO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.avicanna.com
About Avicanna Inc.
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.79M | 4.05M | 3.27M | 1.57M | 168.25K | 117.97K | 26.66K | 0.00 |
| Cost of Revenue | 10.13M | 2.93M | 437.09K | 2.14M | 76.11K | 172.71K | 0.00 | 0.00 |
| Gross Profit | 6.66M | 1.12M | 2.83M | -570.12K | 92.14K | -54.73K | 26.66K | 0.00 |
| Gross Profit Ratio | 39.66% | 27.55% | 86.63% | -36.31% | 54.76% | -46.40% | 100.00% | 0.00% |
| Research & Development | 330.66K | 276.94K | 304.31K | 376.27K | 1.22M | 456.62K | 23.68K | 0.00 |
| General & Administrative | 11.89M | 9.61M | 12.53M | 15.82M | 20.53M | 7.56M | 2.48M | 27.12K |
| Selling & Marketing | 2.37M | 380.08K | 345.91K | 425.64K | 649.32K | 248.73K | 43.92K | 2.71K |
| SG&A | 14.26M | 9.99M | 12.88M | 16.24M | 21.18M | 7.81M | 2.53M | 29.83K |
| Other Expenses | 0.00 | 1.26M | 1.06M | 1.80M | 923.51K | 180.48K | 0.00 | 0.00 |
| Operating Expenses | 14.59M | 11.53M | 14.25M | 18.42M | 23.32M | 8.44M | 2.61M | 29.83K |
| Cost & Expenses | 24.72M | 14.46M | 14.68M | 20.56M | 23.39M | 8.44M | 2.61M | 29.83K |
| Interest Income | 0.00 | 1.67M | 738.06K | 1.00 | 68.93K | 10.36K | 1.45K | 0.00 |
| Interest Expense | 610.26K | 1.67M | 738.06K | 263.11K | 54.76K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 777.29K | 887.33K | 893.99K | 1.09M | 923.51K | 172.71K | 63.24K | 357.98K |
| EBITDA | -7.36M | -12.18M | -15.13M | -33.70M | -22.27M | -7.09M | -2.52M | 328.15K |
| EBITDA Ratio | -43.80% | -239.43% | -304.05% | -1,111.21% | -12,985.12% | -7,647.89% | -9,448.37% | 0.00% |
| Operating Income | -7.93M | -10.58M | -10.83M | -18.53M | -22.77M | -8.32M | -2.58M | -29.83K |
| Operating Income Ratio | -47.24% | -261.35% | -331.40% | -1,180.44% | -13,534.01% | -7,055.81% | -9,685.58% | 0.00% |
| Total Other Income/Expenses | -809.99K | -4.94M | -5.94M | -16.77M | -22.85K | 1.16M | -14.08K | 0.00 |
| Income Before Tax | -8.74M | -14.74M | -16.76M | -35.05M | -23.25M | -7.29M | -2.60M | -29.83K |
| Income Before Tax Ratio | -52.07% | -364.02% | -512.73% | -2,232.35% | -13,816.44% | -6,178.97% | -9,750.46% | 0.00% |
| Income Tax Expense | 0.00 | 2.48M | 13.77K | -2.19M | -1.03M | 1.03M | 1.76K | -357.99K |
| Net Income | -8.74M | -17.22M | -16.77M | -32.86M | -22.21M | -7.10M | -2.60M | -29.83K |
| Net Income Ratio | -52.07% | -425.40% | -513.15% | -2,093.02% | -13,202.24% | -6,017.63% | -9,750.46% | 0.00% |
| EPS | -0.09 | -0.29 | -0.41 | -1.12 | -1.11 | -0.45 | -0.19 | 0.00 |
| EPS Diluted | -0.09 | -0.29 | -0.41 | -1.12 | -1.11 | -0.45 | -0.19 | 0.00 |
| Weighted Avg Shares Out | 84.71M | 59.17M | 41.29M | 29.40M | 20.05M | 15.65M | 13.59M | 10.88M |
| Weighted Avg Shares Out (Dil) | 84.71M | 59.17M | 41.29M | 29.40M | 20.05M | 15.65M | 13.59M | 10.88M |
Source: https://incomestatements.info
Category: Stock Reports